Know Cancer

forgot password

Prevention of Recurrence in Early-Stage,Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax(TM) Treatment

Phase 3
18 Years
Open (Enrolling)
HER2 Negative Breast Cancer

Thank you

Trial Information

Prevention of Recurrence in Early-Stage,Node-Positive Breast Cancer With Low to Intermediate HER2 Expressions With NeuVax(TM) Treatment

This is a multicenter, multinational, prospective, randomized, double-blind, controlled
Phase 3 study.

The subjects eligible for this trial have an early stage Node-Positive (NP) breast cancer.
Their tumors express low or intermediate levels of the HER2 protein. NeuVax™ will be
administered after completion of front-line, standard of care therapy (surgery, radiation
therapy, and chemotherapy) and can be given with physician prescribed endocrine treatment.

The NeuVax will be administered in intradermal injections, in four divided doses (4 sites on
upper thigh) once a month, for six consecutive months. At the end of the six months, NeuVax
vaccine boosters will be given the same way once every six months for the next five times
(totaling 36 months).

The active portion of the study will last three years (36 months). The follow-up will last
from 5 to 10 years.


1. The primary efficacy endpoint is comparing Disease-Free Survival (DFS) in treatment
group versus control group.

2. The secondary efficacy endpoints are

- 5- and 10-year (disease free survival) DFS

- 3-year overall survival (OS)

- 5- and 10-year overall survival (OS), and Overall safety profile and adverse
events (AEs)

Safety Assessments:

Patients will be assessed at every study visit for the safety endpoints AEs,vital signs,
physical examinations and laboratory data; yearly follow-up of survival will include imaging
studies, ECGs, MUGA or ECHO scans and concomitant medications.


Inclusion Criteria:

- Women, 18 years of age and higher

- Pathological diagnosis of invasive adenocarcinoma of the breast

- Breast cancer completely excised

- Node-positive disease

- Primary tumor stage T1-3

- HER2 negative (HER2 1+ by IHC or HER2 2+ by IHC/FISH)

- HLA-A2 or HLA-A3 haplotype

- Completed NCCN approved neo-adjuvant/adjuvant chemotherapy or both

- Completed radiation therapy

- No evidence of disease

Key Exclusion Criteria:

- Bilateral breast malignancy or suspicious mass in opposite breast

- History of prior breast cancer, ductal carcinoma in situ.

- Prior trastuzumab therapy.

- New York Heart Association Stage 3 or 4 cardiac disease

- Sensory/motor neuropathy ≥ Grade 2.

- Autoimmune diseases or immune deficiency disease

- Patients on chronic steroid therapy, other immunosuppressive therapy

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention

Outcome Measure:

Comparison of disease-free survival in vaccine treated patients and control patients

Outcome Description:

The primary objective is to compare the disease-free survival (DFS) in subjects with operable early-stage, node-positive breast cancer who receive standard of care multimodality therapy plus NeuVax™ as the treatment group or standard of care multimodality therapy plus the vaccine adjuvant, Leukine (sargramostim, GM-CSF) as the control group.

Outcome Time Frame:

36 months

Safety Issue:


Principal Investigator

Elizabeth A Mittendorf, MD,FACS

Investigator Role:

Principal Investigator

Investigator Affiliation:

M.D. Anderson Cancer Center


United States: Food and Drug Administration

Study ID:

NeuVax(TM) PH3-01



Start Date:

November 2011

Completion Date:

May 2022

Related Keywords:

  • HER2 Negative Breast Cancer
  • HER2
  • low or intermediate
  • breast cancer
  • node-positive tumors
  • Breast Neoplasms
  • Recurrence



Baylor College of Medicine Houston, Texas  77030
Beth Israel Deaconess Medical Center Boston, Massachusetts  02215
Mary Bird Perkins Cancer Center Baton Rouge, Louisiana  70809
OHSU Knight Cancer Institute Portland, Oregon  97239
University of Texas MD Anderson Cancer Center Houston, Texas  77030
The West Clinic Memphis, Tennessee  38120
Cancer Center of Kansas Wichita, Kansas  67214
Northeast Georgia Cancer Care Athens, Georgia  30607
James Graham Brown Cancer Center, University of Louisville Louisville, Kentucky  40202
Weill Cornell Medical College New York, New York  10021
Central Georgia Cancer Care Macon, Georgia  31201
South Orange County Surgical Medical Group Laguna Hills, California  92653
Virginia Cancer Specialists Fairfax, Virginia  
H.Lee Moffitt Cancer Center and Research Institute Tampa, Florida  33612
Cedars-Sinai Medical Center Samuel Oschin Comprehensive Cancer Institute Los Angeles, California  90048
Moores UC San Diego Cancer Center (UCSD) San Diego, California  92093
University of Colorado Cancer Center, Anschutz Medical Campus Aurora, Colorado  80045
Cancer Specialists of North Florida (ICON) Jacksonville, Florida  32256
MD Anderson Center-Orlando health Orlando, Florida  32806
Florida Cancer Research Institute (Florida Cancer Care) Plantation, Florida  33317
Northwestern University Feinberg School of Medicine, Lynn Sage Comprehensive Breast Center Chicago, Illinois  60611
Center of Cancer and Blood Disorders (VEEDA network) Bethesda, Maryland  20817
Lahey Clinic Department of Hematology and Oncology Burlington, Massachusetts  01805
Eastchester Cancer Care Center Bronx, New York  10469
St. Alexius Medical Center, Mid Dakota Clinic, PC Bismarck, North Dakota  58501
Conemaugh Memorial Hospital-Memorial Medical Center Johnstown, Pennsylvania  15905
Univerity of Pittsburgh Medical Center (UPMC) Cancer Center Pittsburgh, Pennsylvania  15232
UT Southwestern Medical Center / Simmons Comprehensive Cancer Center Dallas, Texas  75390
Brooke Army Medical Center (now SAMMC) Ft. Sam Houston, Texas  78234
Swedish Cancer Institute Research Seattle, Washington  98104
Multicare Health System-Research Institute Tacoma, Washington  98405
Medical College of Wisconsin Department of Surgery Froedtert Hospital and Cancer Center Milwaukee, Wisconsin  52336
Alabama Oncology Bessemer, Alabama  35022
St. Jude Medical Center, Virginia K. Crosson Cancer Center Fullerton, California  92801
University of Southern California/Norris Cancer Hospital Los Angeles, California  90033
University of California, San Francisco (UCSF), Hellen Diller Family Comprehensive Cancer Center San Francisco, California  94115
Stamford Hospital, Bennett Cancer Center Stamford, Connecticut  06904
Holy Cross Hospital-Michael & Dianne Bienes Comprehensive Cancer Center Fort Lauderdale, Florida  33308
Clinical Trials of Texas, Inc San Antonio, Texas  78229